Revenue Growth Across Operations
Total revenues increased 9.6% YoY from $4.10B to $4.50B in Q1 FY2026, reflecting continued demand for healthcare services and capacity utilization improvements across UHS facilities.
来源: 10-Q Income Statement Data
该报告暂无中文版,以下为英文版分析。
按公开的固定规则计算,不是模型的主观判断——但其中一项输入(高等级风险的条数)取自下方的 AI 分析。
非投资建议,也不是目标价——评的是本季基本面,不是股价。 完整方法论 →
AI核心结论
UHS delivered strong Q1 FY2026 results with revenue rising 9.6% YoY to $4.50B and net income growing 10.1% to $348.7M, driven by solid operational performance across its hospital segments.
营收
44.95亿美元
同比 +9.65%
每股收益(稀释)
5.65美元
同比 +17.71%
营业利润
5.03亿美元
同比 +10.56%
SEC XBRL 原值
Universal Health Services (UHS) Q1 FY2026 营收 44.95亿美元,同比增长 9.6%。 营业利润率 11.2%,较去年同期的 11.1% 扩大 0.1 个百分点。 经营活动现金流 4.02亿美元,同比增长 11.5%。 UHS 的财年 Q1 FY2026 对应日历 Q1 2026。
近 4 个季度:2 次超预期
| 季度 | 实际 EPS(美元) | 市场预期(美元) | 结果 |
|---|---|---|---|
| 2026年6月 | 5.98 | 6.02 | 不及预期 -0.6% |
| 2026年3月本次财报 | 5.62 | 5.46 | 超预期 +2.9% |
| 2025年12月 | 5.88 | 5.96 | 不及预期 -1.3% |
| 2025年9月 | 5.69 | 4.88 | 超预期 +16.5% |
2026年3月 调整后(非 GAAP) EPS 5.62美元,分析师一致预期 5.46美元,超预期 +2.9%。 分析师一致预期按市场通行的调整后(非 GAAP)口径。本季 GAAP 稀释每股收益为 5.65美元。
由 AI 基于本次 SEC 报告整理
Total revenues increased 9.6% YoY from $4.10B to $4.50B in Q1 FY2026, reflecting continued demand for healthcare services and capacity utilization improvements across UHS facilities.
来源: 10-Q Income Statement Data
Operating income grew 10.6% YoY to $502.9M, with operating margin modestly improving from 11.09% to 11.19%, indicating disciplined cost management relative to revenue growth.
来源: 10-Q Income Statement Data
Diluted EPS surged 17.7% YoY from $4.80 to $5.65, outpacing net income growth of 10.1%, suggesting that share buybacks ($163.8M in Q1 FY2026) meaningfully reduced the share count and amplified per-share earnings.
来源: 10-Q Income Statement & Cash Flow Data
Operating cash flow increased 11.5% YoY to $401.6M, demonstrating the company's ability to convert earnings into cash, which supports ongoing capital expenditures and shareholder returns.
来源: 10-Q Cash Flow Statement Data
Total assets grew 5.4% YoY to $15.68B, while current liabilities surged 39.2% YoY to $3.24B, compressing the current ratio to approximately 1.08x and warranting monitoring of near-term liquidity.
来源: 10-Q Balance Sheet Data
由 AI 基于本次 SEC 报告整理 · 高 2 中 3 低 0
Current liabilities jumped 39.2% YoY to $3.24B while current assets grew only 13.7% to $3.50B, resulting in a current ratio of just 1.08x. This tightening liquidity position could constrain UHS's financial flexibility if operational cash flows deteriorate.
来源: 10-Q Balance Sheet Data
Long-term debt stands at $4.70B, up 2.2% YoY, representing a significant leverage burden relative to total assets of $15.68B. Rising interest rates could increase debt service costs and pressure net margins going forward.
来源: 10-Q Balance Sheet Data
Cash and equivalents declined 6.1% YoY to $119.0M, a relatively thin cash cushion for a company of UHS's scale. Combined with elevated current liabilities, this limits the buffer available for unexpected operational disruptions.
来源: 10-Q Balance Sheet Data
Financing cash flow swung to an outflow of $221.9M in Q1 FY2026 versus $91.4M in Q1 FY2025, a 142.7% increase in cash used, driven by debt repayments and buybacks. This limits capital available for strategic investments or acquisitions.
来源: 10-Q Cash Flow Statement Data
The healthcare industry, including UHS, faces persistent labor shortages and wage inflation, which can compress margins. While operating margins held relatively stable at 11.19%, sustained labor cost pressures could erode profitability in future quarters.
来源: 10-Q Income Statement Data (inferred from sector context)
| 指标 | 当期 | 上期 | 同比变化 |
|---|---|---|---|
营收 亿美元 | 44.95 亿美元 | 41.00 亿美元 | +9.65% |
营业利润 亿美元 | 5.03 亿美元 | 4.55 亿美元 | +10.56% |
净利润 亿美元 | 3.49 亿美元 | 3.17 亿美元 | +10.11% |
每股收益(基本) 美元 | 5.71 美元 | 4.87 美元 | +17.25% |
每股收益(稀释) 美元 | 5.65 美元 | 4.80 美元 | +17.71% |
答案基于本次 SEC 报告与本页数据
医疗保健设施 行业其他公司